+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoporosis KOL Interviews

  • ID: 4331624
  • Report
  • April 2017
  • Region: Global
  • 29 pages
  • Datamonitor Healthcare
1 of 1

Enquire about COVID-19 updates for this product.

Enquire Now
The author interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges and unmet needs in osteoporosis.

The drugs discussed include abaloparatide (RDUS), Atelvia (AGN), Evenity (AMGN), Evista (LLY), Forteo (LLY), Fosamax (MRK), Prolia (AMGN) and Reclast (NVS).

The two interviews were combined into a single report.
Note: Product cover images may vary from those shown
2 of 1

Loading
LOADING...

Adroll
adroll